Literature DB >> 9559310

Tumor resistance to antimetabolites.

A R Kinsella1, D Smith.   

Abstract

1. The inherent or acquired resistance of certain tumors to cytotoxic drug therapy is a major clinical problem. 2. Resistance to the chemotherapeutic antimetabolites (e.g., methotrexate, 5-fluorouracil, tomudex and gemcitabine) is no exception. 3. Mechanisms of resistance include mutations, amplification of target genes, altered drug transport, differences in nucleoside and nucleobase salvage pathways, DNA damage-response pathways and cell cycle control pathways.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9559310     DOI: 10.1016/s0306-3623(97)00383-2

Source DB:  PubMed          Journal:  Gen Pharmacol        ISSN: 0306-3623


  8 in total

1.  Chemotherapy agents: a primer for the interventional radiologist.

Authors:  Frank Mihlon; Charles E Ray; Wells Messersmith
Journal:  Semin Intervent Radiol       Date:  2010-12       Impact factor: 1.513

2.  Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies.

Authors:  Yujia Wen; Lidija K Gorsic; Heather E Wheeler; Dana M Ziliak; Rong Stephanie Huang; Mary Eileen Dolan
Journal:  Pharmacogenet Genomics       Date:  2011-08       Impact factor: 2.089

3.  Excellent response to gemcitabine in a massively pre-treated woman with extensive cutaneous involvement after recurrence of breast cancer.

Authors:  J Arends; C Unger
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

Review 4.  Novel antifolate drugs.

Authors:  W Thomas Purcell; David S Ettinger
Journal:  Curr Oncol Rep       Date:  2003-03       Impact factor: 5.075

Review 5.  From methotrexate to pemetrexed and beyond. A review of the pharmacodynamic and clinical properties of antifolates.

Authors:  Jackie Walling
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.651

Review 6.  Resveratrol as Chemosensitizer Agent: State of Art and Future Perspectives.

Authors:  Veronica Cocetta; Vincenzo Quagliariello; Francesco Fiorica; Massimiliano Berretta; Monica Montopoli
Journal:  Int J Mol Sci       Date:  2021-02-19       Impact factor: 5.923

7.  Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.

Authors:  Yajie Yu; Jane Ding; Shunqin Zhu; Ahmet Alptekin; Zheng Dong; Chunhong Yan; Yunhong Zha; Han-Fei Ding
Journal:  Cell Death Dis       Date:  2021-08-30       Impact factor: 8.469

8.  Optimized peptide based inhibitors targeting the dihydrofolate reductase pathway in cancer.

Authors:  Amrinder Singh; Neha Deshpande; Nilkamal Pramanik; Siddharth Jhunjhunwala; Annapoorni Rangarajan; Hanudatta S Atreya
Journal:  Sci Rep       Date:  2018-02-16       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.